News

Piramal Pharma Limited has completed the acquisition of 1,46,400 equity shares of Rs 10 each from existing shareholders of Yapan Bio Private Limited for approximately Rs 76 crores, increasing its stake in the contract development and manufacturing organization from 33.33% to 74.00%, thereby making Yapan a subsidiary of Piramal Pharma.

Net Loss of Piramal Pharma reported to Rs 69.39 crore in the quarter ended June 2026 as against net loss of Rs 81.70 crore during the previous quarter ended June 2025. Sales rose 17.39% to Rs 2269.92 crore in the quarter ended June 2026 as against Rs 1933.71 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2269.921933.71 17 OPM %8.605.52 - PBDT216.0997.52 122 PBT-7.46-99.76 93 NP-69.39-81.70 15 Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 29 July 2026.

Piramal Pharma announced that USFDA has issued an Establishment Inspection Report (EIR) for the company`s manufacturing facility located at Sellersville (USA) and the inspection has now been successfully closed by USFDA.

Piramal Pharma announced that the Annual General Meeting(AGM) of the company will be held on 30 July 2026.